Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Benzinga · 3d ago
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.